Investigators compared mortality risk among long-term survivors of high-grade serous ovarian cancer versus the general US population to examine how mortality and recurrence trends have changed with ...
Ovarian cancer mortality rates have declined, but disparities persist across age, race, and geographic regions. Older women, non-Hispanic White women, and those in the Northeast and Midwest have ...
A PILL already used to treat a rare disease could prolong the lives of women with aggressive ovarian cancer, a pivotal trial ...
Platinum-based chemotherapy is a standard treatment for ovarian cancer, but its effectiveness can be limited in some cases. In some patients, the disease returns or progresses within six months of the ...
Dr. Alexander B. Olawaiye presented findings at the 2026 Society of Gynecologic Oncology Annual Meeting showing that adding ...
LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company advancing cancer treatments, ...
Keytruda with paclitaxel, with or without Avastin, improved PFS and OS in PRROC patients, irrespective of PD-L1 status. The trial showed significant benefits in both CPS ≥1 and intention-to-treat ...
A subgroup analysis hints that chemotherapy may be skipped after complete resection, but the finding needs further study.
Rising ovarian and uterine cancer rates are linked to high BMI, with disparities across sociodemographic index levels, particularly in low- and middle-SDI regions. Sarcopenia is prevalent in ...
Nancy Long was a gynecological nurse practitioner when she was diagnosed with ovarian cancer. Yet because the symptoms were so vague, she nearly ignored them. “I missed all the signs and symptoms of ...
The partial hold was triggered by early severe events in new enrollees, including grade 4 neutropenia, grade 4 myocarditis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results